Dimagi receives $25 million to develop transformative technology for Frontline Workers
Program-Related Investment from the Steele Foundation for Hope will fund next generation digital platform to support and enable critical frontline healthcare workforces globally CAMBRIDGE, Mass., Sept. 20, 2022 /PRNewswire/ -- Dimagi, a global social impact organization and leader in frontline technology, announced a $25 million Program-Related Investment (PRI) from the Steele Foundation for Hope. This transformative funding is...
Alterity Therapeutics Receives U.S. FDA Approval for Investigational New Drug Application for ATH434 for the Treatment of Multiple System Atrophy
Regulatory Authorization Granted to Proceed with ATH434 Phase 2 Clinical Trial MELBOURNE, Australia and SAN FRANCISCO, Sept. 20, 2022 /PRNewswire/ -- Alterity Therapeutics (ASX: ATH, NASDAQ: ATHE) ("Alterity" or "the Company"), a biotechnology company dedicated to developing disease modifying treatments for neurodegenerative diseases, today announced the approval of its Investigational New Drug (IND) application...
Menarini and SciClone Sign Exclusive Licensing Agreement to Develop and Commercialize Vaborem® in China to Treat Antimicrobial Resistant Infections
Vaborem®, a patented combination of meropenem and vaborbactam, is expected to address the rising prevalence of carbapenem-resistant Klebsiella pneumoniae (CRKP) infections in China The deal brings together Melinta's innovation, Menarini's cross-regional expertise in registration and marketing this asset, and SciClone's development and commercial presence in China Menarini will receive a...
Jialian Biotech Group To Participate At Vitafoods Asia 2022 In Bangkok
TAIPEI, Sept. 20, 2022 /PRNewswire/ -- Leading Taiwanese health-care supplements manufacturer Jialian Biotech Group (Jialian) is excited to announce its participation in Vitafoods Asia 2022 – Asia's leading nutraceutical event – in Bangkok from October 5th to October 7th, 2022. Headquartered in Taipei City, Taiwan, in addition to OEM/ODM/private label one-stop service, Jialian Biotech Group also offers integrated services,...
WuXi Biologics’ Drug Substance and Drug Product Facilities Again Approved by U.S. FDA and EMA
WUXI, China, Sept. 20, 2022 /PRNewswire/ --WuXi Biologics ("WuXi Bio") (2269.HK), a leading global Contract Research, Development and Manufacturing Organization (CRDMO), today announced that its two Drug Substance (DS) facilities and a Drug Product (DP) facility located in Wuxi city received regulatory approvals from the European Medicines Agency (EMA) and the U.S. Food and Drug Administration (FDA). After passing...
Rapid growth puts Australian CRO Accelagen on the map for clinical research globally
With over 110% revenue growth in the last two years, Accelagen announces move to new office space in Hawthorn East, Melbourne MELBOURNE, Australia, Sept. 20, 2022 /PRNewswire/ -- Accelagen, one of Australia's leading Contract Research Organisations, has taken new 472sqM office space in Hawthorn East following two years of rapid growth for the business. Accelagen_New HQ...
Unstoppable Rise of Korean Medical Tourism
KHIDI Launches Official Medical Korea Website for Easier Access to Korean Medical Services SEOUL, South Korea, Sept. 20, 2022 /PRNewswire/ -- Korea Health Industry Development Institute (KHIDI) has revamped the official website of Medical Korea(www.medicalkorea.or.kr), featuring information related to the use of Korean medical services. Unstoppable Rise of Korean Medical Tourism! Korea has been awarded by the...
Smith+Nephew launches OR3O™ Dual Mobility System in Japan for use in primary and revision hip arthroplasty
Features proprietary OXINIUM™ DH material; eliminates Cobalt Chrome alloy reducing wear and corrosion risks1 LONDON, Sept. 20, 2022 /PRNewswire/ -- Smith+Nephew (LSE:SN, NYSE:SNN), the global medical technology business, today announces the launch of its OR3O Dual Mobility System for use in primary and revision hip arthroplasty in Japan. Compared with traditional solutions,...
Waterdrop Launches the WFind System
BEIJING, Sept. 19, 2022 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare service with a positive social impact, recently launched "Waterdrop Family Insurance Needs Diagnosis" ("WFind"), a system designed to help insurance brokers identify customer insurance needs based on information about their family members, income & expenses,...
RemeGen Announces Preliminary Results of Phase III Confirmatory Study of Telitacicept for Treatment of Systemic Lupus Erythematosus (SLE) in China
YANTAI, China, Sept. 19, 2022 /PRNewswire/ -- RemeGen Co., Ltd. ("RemeGen" or "the Company") (9995.HK, SHA: 688331), a commercial-stage biotechnology company, recently announced the preliminary results of the Phase III confirmatory study of its proprietary novel fusion protein Telitacicept for the treatment of systemic lupus erythematosus (SLE) in China. The study included 335 patients who were randomized to weekly subcutaneous...
